[1]
F. Greco, M. J. Vicent, Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines, Adv. Drug Delivery Rev. 61 (2009) 1203-1213.
DOI: 10.1016/j.addr.2009.05.006
Google Scholar
[2]
E. Siris, Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Womens Health Gend Based Med, 9(2000) 599- 606.
Google Scholar
[3]
P. Masarachia, M. Weinreb, R. Balena, G.A. Rodan, Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones, Bone. 19(1996) 281-290.
DOI: 10.1016/8756-3282(96)00182-2
Google Scholar
[4]
H. Uludag, J. Yang, Targeting systemically administered proteins to bon by bisphosphonate conjugation. Biotechnol Prog. 18(2002) 604-611.
DOI: 10.1021/bp0200447
Google Scholar
[5]
K. A. Janes, P. Calvo,M. J. Alonso, Polysaccharide colloidal particles as delivery system for macromolecules, Adv. Drug Delivery Rev. 47(2001) 83-97.
DOI: 10.1016/s0169-409x(00)00123-x
Google Scholar
[6]
M. Thanou, J. C. Verhoef, H. E. Junginger, Oral drug absorption enhancement by chitosan and its derivatives, Adv. Drug Delivery Rev. 52(2001) 117.
DOI: 10.1016/s0169-409x(01)00231-9
Google Scholar
[7]
G.Q. Cai, H.L. Jiang, K.H. Tu, L.Q. Wang, K.J. Zhu, A facile route for regioselective conjugation of organo-soluble polymers onto chitosan, Macromol. Biosci. 9(2009) 256-261.
DOI: 10.1002/mabi.200800153
Google Scholar
[8]
R. Huang, Y. Du, J. Yang, Preparation and anticoagulant activity of carboxybutyrylated hydroxyethyl chitosan sulfates, Carbohydr. Polym. 51(2003) 431-438.
DOI: 10.1016/s0144-8617(02)00208-4
Google Scholar